A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza

A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years

This partially randomized, multi-center parallel-group study will evaluate the safety, pharmacokinetics and the effect on viral load and viral shedding of Tamiflu (Oseltamivir) in patients with influenza. Adult and adolescent patients will be randomized to receive either 100 mg or 200 mg of study drug intravenously every 12 hours. Investigators and patients are blinded to knowledge of the assigned dose of Tamiflu. There is an option to convert to oral Tamiflu after 6 intravenous infusions. The anticipated time on study treatment is 5 days, with an optional treatment extension of a further 5 days, if necessary. There will be a non-randomized, open-label treatment group for patients with moderate/severe renal impairment or renal failure. Intravenous dose levels and frequency will be adjusted appropriately to their renal situation.

Study Overview

• Status: Completed
• Conditions: Influenza
• Intervention / Treatment: Drug: Oseltamivir IV; Drug: Oseltamivir Oral

• Study Type: Interventional
• Enrollment (Actual): 118
• Phase: Phase 3

Contacts and Locations

Study Locations

• Denmark
  • Odense C, Denmark, 5000
• France
  • Bron, France, 69677
  • Garches, France, 92380
  • La Tronche, France, 38700
  • Paris, France, 75970
  • Paris, France, 75651
  • Paris, France, 75679
  • Tours, France, 37044
• Hungary
  • Budapest, Hungary, 1125
  • Budapest, Hungary, 1097
  • Debrecen, Hungary, 4012
  • Eger, Hungary, 3300
  • Gyor, Hungary, 9024
  • Gyula, Hungary, 5700
  • Kaposvar, Hungary, 7400
  • Miskolc, Hungary, 3526
  • Nyiregyhaza, Hungary, 4400
  • Pecs, Hungary, 7624
  • Szeged, Hungary, 6725
  • Szolnok, Hungary, 5000
  • Szombathely, Hungary, 9700
  • Veszprem, Hungary, H-8200
• Italy
  • Genova, Italy, 16132
  • Milano, Italy, 20157
  • Monza, Italy, 20052
  • Pavia, Italy, 27100
  • Roma, Italy, 00149
• Lithuania
  • Kaunas, Lithuania, 47116
  • Vilnius, Lithuania, 08117
• Poland
  • Bialystok, Poland, 15-540
  • Chorzow, Poland, 41-500
  • Radom, Poland, 26-610
  • Warszawa, Poland, 01-201
• Romania
  • Bucharest, Romania, 21105
  • Constanta, Romania, 8700
  • Craiova, Romania, 200515
  • Timisoara, Romania, 300310
• Spain
  • Almeria, Spain, 04009
  • Madrid, Spain, 28905
  • Alicante
    • Elche, Alicante, Spain, 03203
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35233
    • Montgomery, Alabama, United States, 36106
  • Arizona
    • Phoenix, Arizona, United States, 85008
  • Arkansas
    • Little Rock, Arkansas, United States, 72205
  • California
    • Duarte, California, United States, 91010
    • Los Angeles, California, United States, 90027
    • San Diego, California, United States, 92120
  • Delaware
    • Wilmington, Delaware, United States, 19803
  • Florida
    • Melbourne, Florida, United States, 32901
    • Miami, Florida, United States, 33126
    • Pensacola, Florida, United States, 32504
    • South Miami, Florida, United States, 33143
    • Tampa, Florida, United States, 33606
  • Georgia
    • Atlanta, Georgia, United States, 30309
  • Illinois
    • Chicago, Illinois, United States, 60637
    • Chicago, Illinois, United States, 60612
    • Maywood, Illinois, United States, 60153
  • Iowa
    • Des Moines, Iowa, United States, 50314
  • Kansas
    • Kansas City, Kansas, United States, 64128
    • Overland Park, Kansas, United States, 66211
    • Wichita, Kansas, United States, 67214
  • Kentucky
    • Madisonville, Kentucky, United States, 42431
  • Louisiana
    • New Orleans, Louisiana, United States, 70121
  • Massachusetts
    • Worcester, Massachusetts, United States, 01655
  • Michigan
    • Detroit, Michigan, United States, 48202
    • Kalamazoo, Michigan, United States, 49007
  • Minnesota
    • Duluth, Minnesota, United States, 55805
    • Minneapolis, Minnesota, United States, 55454
  • Mississippi
    • Jackson, Mississippi, United States, 39202
  • Missouri
    • St. Joseph, Missouri, United States, 64506
  • Montana
    • Butte, Montana, United States, 59701
  • Nebraska
    • Grand Island, Nebraska, United States, 68803
  • New Jersey
    • Holmdel, New Jersey, United States, 07733
  • New York
    • Bronx, New York, United States, 10467
    • New York, New York, United States, 10032
    • New York, New York, United States, 10065
    • New York, New York, United States, 10007
    • South Bronx, New York, United States, 10461
    • Stony Brook, New York, United States, 11794
  • North Carolina
    • Charlotte, North Carolina, United States, 28233
    • Winston-Salem, North Carolina, United States, 27103
  • Ohio
    • Akron, Ohio, United States, 44304
    • Cincinnati, Ohio, United States, 45229
    • Cincinnati, Ohio, United States, 45267
    • Cleveland, Ohio, United States, 44109
    • Dayton, Ohio, United States, 45404
    • Youngstown, Ohio, United States, 44501
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73104
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19106
    • Pittsburgh, Pennsylvania, United States, 15213-2582
  • Texas
    • Dallas, Texas, United States, 75216
    • Dallas, Texas, United States, 75235
    • San Antonio, Texas, United States, 78205
    • San Antonio, Texas, United States, 78232
  • Virginia
    • Norfolk, Virginia, United States, 23510
  • West Virginia
    • Charleston, West Virginia, United States, 25304

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 13 years and older (ADULT, OLDER_ADULT, CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Adult and adolescent patients, 13 years of age and older
• Diagnosis of influenza
• ≤ 144 hours between the onset of influenza-like illness and first dose of study drug

Non-randomized, open-label treatment group:

• Patients with moderate/severe renal impairment or renal failure with creatinine clearance 10-60 mL/min

Exclusion Criteria:

• Clinical evidence of severe hepatic decompensation at the time of randomization
• Acute ischemia or significant arrhythmia

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Oseltamivir (TAMIFLU®) 100 mg; Oseltamivir (TAMIFLU®) 100 mg intravenous (IV) infused over 2 hours, two times a day (every 12 hours) for 5 days. At the discretion of the investigator after 3 days of treatment (6 doses), participants could either continue IV treatment or switch to 75 mg oral oseltamivir twice daily to complete the 5 days of treatment. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug (IV or oral) for up to 5 days.	Drug: Oseltamivir IV; Oseltamivir IV infusions over 2 hours two times a day (every 12 hours) for 5 days for patients with moderate renal impairment. Patients with severe renal impairment received once daily dosing and patients on renal replacement therapy received dose/frequency according to protocol.; Other Names: TAMIFLU®; Drug: Oseltamivir Oral; Oseltamivir (TAMIFLU®) capsules taken orally for 5 days. Twice daily (every 12 hours) for patients with moderate renal impairment, once daily for patients with severe renal impairment and dose frequency according to protocol for patients on renal replacement therapy.; Other Names: TAMIFLU®
EXPERIMENTAL: Oseltamivir (TAMIFLU®) 200 mg; Oseltamivir (TAMIFLU®) 200 mg intravenous (IV) infused over 2 hours, two times a day (every 12 hours) for 5 days. At the discretion of the investigator after 3 days of treatment (6 doses), participants could either continue IV treatment or switch to 150 mg oral oseltamivir twice daily for 5 days. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug (IV or oral) for up to 5 days.	Drug: Oseltamivir IV; Oseltamivir IV infusions over 2 hours two times a day (every 12 hours) for 5 days for patients with moderate renal impairment. Patients with severe renal impairment received once daily dosing and patients on renal replacement therapy received dose/frequency according to protocol.; Other Names: TAMIFLU®; Drug: Oseltamivir Oral; Oseltamivir (TAMIFLU®) capsules taken orally for 5 days. Twice daily (every 12 hours) for patients with moderate renal impairment, once daily for patients with severe renal impairment and dose frequency according to protocol for patients on renal replacement therapy.; Other Names: TAMIFLU®
EXPERIMENTAL: Oseltamivir Open Label; Moderate/Severe renal impaired participants received open label oseltamivir IV or oseltamivir capsules at reduced doses for 5 days as per protocol. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug as per protocol.	Drug: Oseltamivir IV; Oseltamivir IV infusions over 2 hours two times a day (every 12 hours) for 5 days for patients with moderate renal impairment. Patients with severe renal impairment received once daily dosing and patients on renal replacement therapy received dose/frequency according to protocol.; Other Names: TAMIFLU®; Drug: Oseltamivir Oral; Oseltamivir (TAMIFLU®) capsules taken orally for 5 days. Twice daily (every 12 hours) for patients with moderate renal impairment, once daily for patients with severe renal impairment and dose frequency according to protocol for patients on renal replacement therapy.; Other Names: TAMIFLU®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Adverse Events (AEs), Serious Adverse Events(SAEs, AEs Leading to Withdrawal, and Death	Safety was assessed by adverse events (AEs) as measured by the collection of AEs, vital signs, electrocardiograms and laboratory parameters. An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. On treatment = AEs that started between the day of first dose and within 2 days after the last dose. Off treatment = AEs that started more than 2 days after the last dose of study drug.	Up to 30 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics		Days 1, 3
Percentage of Participants With Viral Shedding by Culture or RT-PCR	Nasal and throat swabs were collected on Days 1, 4, 6, 11, 15, and 30 and were sent to a central laboratory for analysis. The presence of viral shedding was determined by a positive culture [log10 median tissue culture infective dose (TCID50) > 0.5) or detection by RT-PCR (log 10 copies/mL).	Days 1, 4, 6, 11, 15 and 30
Percentage of Participants With Viral Shedding by Culture	Nasal and throat swabs were collected on Days 1, 4, 6, 11, 15, and 30 and were sent to a central laboratory for analysis. The presence of viral shedding was determined by a positive culture=log10 median tissue culture infective dose (TCID50) > 0.5.	Days 1, 4, 6, 11, 15, 30
Percentage of Participants With Viral Shedding by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)	Nasal and throat swabs were collected on Days 1, 4, 6, 11, 15, and 30 and were sent to a central laboratory for analysis. The presence of viral shedding was determined by detection by RT-PCR (log 10 copies/mL).	Days 1, 4, 6, 11, 15 and 30
Change From Baseline in Influenza Titer by Culture at Day 4	Nasal and throat swabs collected at Baseline and Day 4 were sent to a laboratory for analysis. Viral influenza titer (amount of virus present) was determined by culture. A log 10 median tissue culture infective dose (TCID50) > 0.5= Positive culture. A negative change from Baseline indicated improvement (less virus present).	Baseline, Day 4
Change From Baseline in Influenza Titer by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) at Day 4	Nasal and throat swabs were collected at Baseline and Day 4 and were sent to a central laboratory for analysis. Influenza Viral titers (amount of virus present) were determined by RT-PCR for Flu A and Flu B and were reported in log 10 copies/milliliter (mL). A negative change from Baseline indicated improvement (less virus present).	Baseline, Day 4
Percentage of Participants Who Had a Fever During the Study	Fever was defined as a temperature of ≥ 37.8 C (degrees Celcius).	Baseline and Hours 12, 24, 36, 48, 60, 72, 84, 96 and 108
Time to Resolution of Fever for Participants Who Had a Fever at Baseline	Fever was defined as a temperature of ≥ 37.8 C (degrees Celsius). Resolution of fever was a temperature ≤ 37.2 for at least 21.5 hours.	Baseline, Up to 30 Days
Number of Participants With Viral Resistance	Nasal and Throat swabs were collected on Days 1, 4, 6, 11, 15 and 30 and were sent to a central laboratory for testing. Viral resistance was determined by phenotypic and genotypic testing.	30 days
Percentage of Participants With Influenza Symptoms	Influenza (flu) symptoms were nasal congestion, sore throat, cough, aches and pains, fatigue, headache or chills.	Days 1, 11, 15, 30

Collaborators and Investigators

• Sponsor: Hoffmann-La Roche

Study record dates

Study Major Dates

• Study Start: January 1, 2010
• Primary Completion (ACTUAL): September 1, 2012
• Study Completion (ACTUAL): September 1, 2012

Study Registration Dates

• First Submitted: January 14, 2010
• First Submitted That Met QC Criteria: January 14, 2010
• First Posted (ESTIMATE): January 15, 2010

Study Record Updates

• Last Update Posted (ESTIMATE): November 1, 2013
• Last Update Submitted That Met QC Criteria: August 28, 2013
• Last Verified: August 1, 2013

More Information

Terms related to this study

• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Orthomyxoviridae Infections; Influenza, Human; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Enzyme Inhibitors; Oseltamivir
• Other Study ID Numbers: NV25118